| scholarly article | Q13442814 |
| P2093 | author name string | Mary L Disis | |
| P2860 | cites work | Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 |
| Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 | ||
| Inflammation and cancer | Q24649640 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer | Q24685406 | ||
| Cancer-related inflammation | Q27860907 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Interferons, immunity and cancer immunoediting | Q28270336 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon | Q33464837 | ||
| Prognostic significance of autoimmunity during treatment of melanoma with interferon. | Q44019499 | ||
| A controlled trial of a human papillomavirus type 16 vaccine | Q44366335 | ||
| De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent | Q46068963 | ||
| Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. | Q46165919 | ||
| Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity | Q46719117 | ||
| Evidence for immune defects in breast and lung cancer patients | Q47375707 | ||
| Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations. | Q51802732 | ||
| High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. | Q53253117 | ||
| Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. | Q53332082 | ||
| Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures | Q56965922 | ||
| Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers | Q56966054 | ||
| Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer | Q57254166 | ||
| Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse | Q58211903 | ||
| Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients | Q68640720 | ||
| Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients | Q79351956 | ||
| Biologic predictors in follicular lymphoma: importance of markers of immune response | Q80164904 | ||
| TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer | Q80241015 | ||
| Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response | Q80582229 | ||
| High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma | Q81351659 | ||
| Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection | Q82645758 | ||
| An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer | Q83133034 | ||
| IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host | Q84080110 | ||
| Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment | Q84793633 | ||
| Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients | Q33508227 | ||
| Effector memory T cells, early metastasis, and survival in colorectal cancer | Q33992461 | ||
| Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells | Q34147162 | ||
| Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. | Q34371245 | ||
| Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer | Q34543188 | ||
| Friendly and dangerous signals: is the tissue in control? | Q34593031 | ||
| PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients | Q34606735 | ||
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 | ||
| Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. | Q34657638 | ||
| The sound of silence: modulating anergy in T lymphocytes. | Q34704118 | ||
| CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages | Q34995099 | ||
| The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research | Q35000726 | ||
| The current status of intravesical therapy for superficial bladder cancer | Q35199096 | ||
| Cancer vaccines: between the idea and the reality | Q35219026 | ||
| CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma | Q35676736 | ||
| Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection | Q35724734 | ||
| Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma | Q36371068 | ||
| CD4 regulatory T cells in human cancer pathogenesis | Q36526954 | ||
| Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. | Q36787548 | ||
| Polarized immune responses differentially regulate cancer development | Q36808629 | ||
| Mechanism of action and other potential roles of an immune response modifier | Q36824851 | ||
| BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma | Q36837124 | ||
| The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages | Q36959353 | ||
| Inflammation: a driving force speeds cancer metastasis | Q36986448 | ||
| Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. | Q37133445 | ||
| Macrophage polarization in tumour progression | Q37158140 | ||
| The Janus face of dendritic cells in cancer | Q37287170 | ||
| Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer | Q37369840 | ||
| Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? | Q37493607 | ||
| Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity | Q37578374 | ||
| Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia | Q39296306 | ||
| Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma | Q39888328 | ||
| A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. | Q39937853 | ||
| Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma | Q40795774 | ||
| Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma | Q40974941 | ||
| Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. | Q42024502 | ||
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4531-4538 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Immune regulation of cancer | |
| P478 | volume | 28 |
| Q28393278 | A multi-targeted approach to suppress tumor-promoting inflammation |
| Q40887427 | A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit |
| Q38674589 | A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. |
| Q38541959 | ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW. |
| Q35791247 | Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. |
| Q39129112 | Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway |
| Q30316394 | Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis |
| Q36866472 | Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β. |
| Q38525034 | Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors |
| Q64060058 | Allergic Signs in Glioma Pathology: Current Knowledge and Future Perspectives |
| Q38803301 | An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors |
| Q27028000 | An immunologic portrait of cancer |
| Q91558300 | An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma |
| Q38834918 | An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth. |
| Q55362655 | Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis. |
| Q93098401 | Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma |
| Q33759287 | B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis |
| Q47158235 | Beyond cancer genes: colorectal cancer as robust intrinsic states formed by molecular interactions. |
| Q36537204 | Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients |
| Q88795324 | CORR Insights®: Intratibial Injection Causes Direct Pulmonary Seeding of Osteosarcoma Cells and Is Not a Spontaneous Model Metastasis: A Mouse Osteosarcoma Model |
| Q37396270 | Can immunity to breast cancer eliminate residual micrometastases? |
| Q33646584 | Cancer Immunoprevention and Public Health |
| Q35666338 | Cancer immunotherapy comes of age |
| Q26866298 | Cannabinoids as therapeutic agents in cancer: current status and future implications |
| Q41886675 | Changes in the NFκB and E-cadherin expression are associated to diabetic nephropathy inPsammomys obesus |
| Q90484961 | Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond |
| Q37392676 | Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer |
| Q36740855 | Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review |
| Q34621713 | Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab |
| Q28396029 | Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer |
| Q92926171 | Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment |
| Q37437301 | Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment |
| Q35667739 | Current status of immunotherapy for the treatment of lung cancer. |
| Q35475443 | Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. |
| Q47103934 | Cytokines in Male Fertility and Reproductive Pathologies: Immunoregulation and Beyond |
| Q41325762 | DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time |
| Q36007456 | Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells |
| Q38281782 | Dendritic cell-based vaccine research against cancer. |
| Q46705056 | Differences in cerebrospinal fluid inflammatory cell reaction of patients with leptomeningeal involvement by lymphoma and carcinoma. |
| Q40963026 | Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients |
| Q47128387 | Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis |
| Q96128419 | Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration |
| Q38828829 | Engineered T cells: the promise and challenges of cancer immunotherapy. |
| Q90311523 | Epigenetic Regulation of Inflammatory Cytokine-Induced Epithelial-To-Mesenchymal Cell Transition and Cancer Stem Cell Generation |
| Q37515861 | Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma |
| Q36425747 | Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes |
| Q37111149 | Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression |
| Q37305086 | Formal modeling and analysis of the hexosamine biosynthetic pathway: role of O-linked N-acetylglucosamine transferase in oncogenesis and cancer progression |
| Q26765123 | From bench to bedside a comprehensive review of pancreatic cancer immunotherapy |
| Q82448827 | Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination |
| Q41195455 | Gene expression profiling of calcifications in breast cancer |
| Q47739176 | Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma |
| Q58705289 | Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression |
| Q36373347 | High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes |
| Q92839456 | High preoperative peripheral blood neutrophil predicts poor outcome in rectal cancer treated with neoadjunctive chemoradiation therapy |
| Q54858561 | Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. |
| Q89519141 | Identification of cancer driver genes based on nucleotide context |
| Q37689695 | Immune approaches to the treatment of breast cancer, around the corner? |
| Q37848665 | Immune parameters affecting the efficacy of chemotherapeutic regimens |
| Q91238304 | Immuno-Oncology in the Era of Personalized Medicine |
| Q37827418 | Immunologic biomarkers as correlates of clinical response to cancer immunotherapy |
| Q34187221 | Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. |
| Q33858844 | Immunological network signatures of cancer progression and survival |
| Q52592731 | Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. |
| Q39218636 | Immunotherapy for colorectal cancer: where are we heading? |
| Q35567765 | Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. |
| Q26781538 | Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials |
| Q92503954 | Immunotherapy in breast cancer |
| Q35693475 | Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival |
| Q52683991 | Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). |
| Q36619126 | Infiltrating neutrophils increase bladder cancer cell invasion via modulation of androgen receptor (AR)/MMP13 signals |
| Q39273621 | Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment |
| Q37697529 | Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond. |
| Q34977106 | Innate immunity pathways and breast cancer Risk in African American and European-American women in the Women's Circle of Health Study (WCHS). |
| Q36834266 | Intercellular adhesion molecule-1 mediates murine colon adenocarcinoma invasion |
| Q64236794 | Isoalantolactone inhibits IKKβ kinase activity to interrupt the NF-κB/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin in glioblastoma |
| Q35166659 | Kinome expression profiling and prognosis of basal breast cancers |
| Q47222619 | LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. |
| Q33667485 | Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. |
| Q55343224 | Learning on the Fly: The Interplay between Caspases and Cancer. |
| Q33903133 | Lenalidomide enhances anti-myeloma cellular immunity |
| Q35231060 | Macrophages support splenic erythropoiesis in 4T1 tumor-bearing mice |
| Q26798404 | Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy |
| Q40188505 | Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment |
| Q58735629 | Molecular mechanism of activated T cells in breast cancer |
| Q46026307 | Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. |
| Q42846034 | Multimodal cancer care research |
| Q89976160 | Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer |
| Q42700735 | Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding. |
| Q38953461 | Novel immunotherapy in the treatment of advanced non-small cell lung cancer |
| Q43152790 | On the prognostic & predictive impact of immune cells system in colorectal cancer. |
| Q57050806 | Oncogenic Signaling Induced by HCV Infection |
| Q38025696 | Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy. |
| Q37747899 | Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study |
| Q38222469 | PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy |
| Q64883722 | PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. |
| Q41626811 | Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence |
| Q104077145 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial |
| Q38293525 | Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer |
| Q90484035 | Perplexing Role of P-Glycoprotein in Tumor Microenvironment |
| Q36879415 | Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors |
| Q33800747 | Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children |
| Q43608671 | Prediction of local recurrence in cervical cancer by a Cox model comprised of lymph node status, lymph-vascular space invasion, and intratumoral Th17 cell-infiltration |
| Q35402584 | Profile of differentially expressed intratumoral cytokines to predict the immune-polarizing side effects of tamoxifen in breast cancer treatment |
| Q55025383 | Prognostic significance of NF-κB expression in non-small cell lung cancer: A meta-analysis. |
| Q36541196 | Prognostic value of innate and adaptive immunity in colorectal cancer |
| Q35060987 | Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial |
| Q58089143 | Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade |
| Q35559050 | Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. |
| Q50438156 | Redefining clinical risk classification in children with precursor B cell acute lymphoblastic leukemia using pre-treatment absolute lymphocyte count |
| Q40056515 | Regulation of Metabolism Across Different Subsets of T Cells in Cancer |
| Q42084378 | Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence |
| Q38170384 | Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. |
| Q52722878 | Roles of NF-κB Signaling in the Regulation of miRNAs Impacting on Inflammation in Cancer. |
| Q92704401 | STAT3 Inhibits CD103+ cDC1 Vaccine Efficacy in Murine Breast Cancer |
| Q47169813 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. |
| Q61807041 | Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer |
| Q37297487 | Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer |
| Q59335796 | Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology |
| Q26823497 | Solid tumors in young patients |
| Q47131425 | Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab |
| Q36127604 | Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia. |
| Q40386096 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group |
| Q54115289 | Subunit-Specific Role of NF-κB in Cancer. |
| Q50700728 | Suppressing the molecular signaling pathways involved in inflammation and cancer in breast cancer cell lines MDA-MB-231 and MCF-7 by miR-590. |
| Q90152385 | The Antitumor Efficacy of β-Elemene by Changing Tumor Inflammatory Environment and Tumor Microenvironment |
| Q92288157 | The Prognostic Importance of CD20+ B lymphocytes in Colorectal Cancer and the Relation to Other Immune Cell subsets |
| Q57291725 | The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2 |
| Q33688982 | The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5. |
| Q37970005 | The clinical implications of antitumor immunity in head and neck cancer |
| Q38126565 | The complexity of NF-κB signaling in inflammation and cancer |
| Q38827388 | The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients |
| Q37531844 | The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients |
| Q38469671 | The evolving role of the endocannabinoid system in gynaecological cancer |
| Q37172099 | The invisible arm of immunity in common cancer chemoprevention agents |
| Q90003208 | The multifaceted immune regulation of bladder cancer |
| Q39452499 | The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review |
| Q38211077 | The role of inflammation in prostate cancer |
| Q33765986 | The roles of regulatory B cells in cancer |
| Q42143991 | The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response |
| Q35193892 | Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept |
| Q50606627 | Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. |
| Q64122281 | Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells |
| Q37609774 | Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab |
| Q90776028 | Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients |
| Q38085028 | Tremelimumab: a review of development to date in solid tumors |
| Q36450516 | Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope? |
| Q35890610 | Tumor-Associated Glycans and Immune Surveillance |
| Q90370299 | Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival |
| Q97587323 | Tumors induce de novo steroid biosynthesis in T cells to evade immunity |
| Q27005794 | Understanding high endothelial venules: Lessons for cancer immunology |
| Q38076053 | Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. |
| Q55343122 | Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients. |
| Q52319565 | mTOR at the Transmitting and Receiving Ends in Tumor Immunity. |
| Q37604616 | miR-15a-3p and miR-16-1-3p Negatively Regulate Twist1 to Repress Gastric Cancer Cell Invasion and Metastasis |
| Q37536367 | nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors |
Search more.